How does SVA's PB Ratio compare to its peers?

SVA has negative equity and a Price-To-Book Ratio (-6.2x) compared to the peer average (5.7x).

How does SVA's PB Ratio compare vs other companies in the CA Biotechs Industry?

SVA has negative equity and a Price-To-Book Ratio (-6.2x) compared to the Canadian Biotechs industry average (1.5x).

What is SVA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate SVA's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of SVA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate SVA's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Sernova (TSX:SVA) - Stock Price, News & Analysis

SVA Stock Overview

Operates as a clinical-stage regenerative medicine therapeutics company in Canada. More details

SVA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Earnings are forecast to grow 61.39% per year

Risk Analysis

Negative shareholders equity

Makes less than USD$1m in revenue (CA$0)

Does not have a meaningful market cap (CA$75M)

Sernova Corp. Competitors

Satellos Bioscience

TSX:MSCL

CA$86.2m

Covalon Technologies

TSXV:COV

CA$109.6m

Oncolytics Biotech

TSX:ONC

CA$114.1m

Microbix Biosystems

TSX:MBX

CA$42.7m

Price History & Performance

Summary of all time highs, changes and price drops for Sernova
Historical stock prices
Current Share Price	CA$0.24
52 Week High	CA$0.77
52 Week Low	CA$0.20
Beta	1.32
11 Month Change	-5.88%
3 Month Change	9.09%
1 Year Change	-65.22%
33 Year Change	-82.48%
5 Year Change	26.32%
Change since IPO	-93.33%

Recent updates

Here's Why We're Not At All Concerned With Sernova's (CVE:SVA) Cash Burn Situation

Feb 23

We Think Sernova (CVE:SVA) Can Easily Afford To Drive Business Growth

Aug 11

Shareholder Returns

	SVA	CA Biotechs	CA Market
7D	4.3%	-8.5%	0.7%
1Y	-65.2%	1.5%	21.7%

Return vs Industry: SVA underperformed the Canadian Biotechs industry which returned -0.4% over the past year.

Return vs Market: SVA underperformed the Canadian Market which returned 21.4% over the past year.

Price Volatility

Is SVA's price volatile compared to industry and market?
SVA volatility
SVA Average Weekly Movement	10.1%
Biotechs Industry Average Movement	11.7%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.6%
10% least volatile stocks in CA Market	2.9%

Stable Share Price: SVA has not had significant price volatility in the past 3 months compared to the Canadian market.

Volatility Over Time: SVA's weekly volatility (10%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1998	n/a	n/a	www.sernova.com

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs.

Sernova Corp. Fundamentals Summary

How do Sernova's earnings and revenue compare to its market cap?
SVA fundamental statistics
Market cap	CA$74.82m
Earnings (TTM)	-CA$38.93m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-2.0x

P/E Ratio

Is SVA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SVA income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$38.93m
Earnings	-CA$38.93m

Last Reported Earnings

Jul 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.12
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did SVA perform over the long term?

See historical performance and comparison

SVA Stock Overview

Rewards

Risk Analysis

Sernova Corp. Competitors

TSX:MSCL

CA$86.2m

TSXV:COV

CA$109.6m

TSX:ONC

CA$114.1m

TSX:MBX

CA$42.7m

Price History & Performance

Recent News & Updates

Forecast to breakeven in 2027

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Price target decreased by 18% to CA$2.88

Sernova Corp. Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sernova Corp. announced that it has received CAD 5.2 million in funding

Independent Director recently sold CA$223k worth of stock

Recent updates

Forecast to breakeven in 2027

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Price target decreased by 18% to CA$2.88

Sernova Corp. Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sernova Corp. announced that it has received CAD 5.2 million in funding

Independent Director recently sold CA$223k worth of stock

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Price target decreased by 14% to CA$3.52

Less than half of directors are independent

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

New minor risk - Share price stability

New minor risk - Market cap size

Price target decreased by 13% to CA$3.53

Sernova Corp., Annual General Meeting, Apr 30, 2024

New minor risk - Financial position

Companies Like Sernova (TSE:SVA) Are In A Position To Invest In Growth

Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting

Price target decreased by 16% to CA$3.52

Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

We're Keeping An Eye On Sernova's (TSE:SVA) Cash Burn Rate

Chairman recently bought CA$238k worth of stock

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™? at American Diabetes Association 83rd Scientific Sessions

New major risk - Financial position

Sernova Corp. Announces Executive Changes

Less than half of directors are independent

We Think Sernova (TSE:SVA) Can Afford To Drive Business Growth

Sernova Corp., Annual General Meeting, Apr 27, 2023

Sernova Announces Advancements with Its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Sernova Corp. Announces Executive Changes

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of Its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Price target increased to CA$4.21

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

We Think Sernova (TSE:SVA) Can Afford To Drive Business Growth

Sernova Corp. Appoints Daniel Mahony, Ph.D. to Its Board of Directors, Effective from September 30, 2022

Executive Chairman of the Board recently bought CA$65k worth of stock

Sernova Corp. Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System Tm at American Diabetes Association 82nd Scientific Sessions 2022

Sernova Corp.(TSXV:SVA) dropped from S&P/TSX Venture Composite Index

Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evotec SE

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation At American Diabetes Association 82Nd Scientific Sessions 2022

No longer forecast to breakeven

Here's Why We're Not At All Concerned With Sernova's (CVE:SVA) Cash Burn Situation

Sernova Corp., Annual General Meeting, Apr 28, 2022

Sernova Corp. Announces Publication of A Peer Reviewed Preclinical Study Demonstrating Positive Results of A Novel Cell Pouch System Cell Therapy

Sernova Corp. Provides Progress Update on Its Phase 1/2 T1d Clinical Trial

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Forecast to breakeven in 2024

We Think Sernova (CVE:SVA) Can Easily Afford To Drive Business Growth

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Chief Financial Officer recently bought CA$78k worth of stock

Sernova Corp. has completed a Composite Units Offering in the amount of CAD 20.04 million.

Sernova Corp Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System Clinical Trial and Recommendation for Protocol Continuation

Independent Chairman exercised options to buy CA$272k worth of stock.